Bacterial Infections  >>  Sivextro (tedizolid)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
ABSSSI, NCT01170221: TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Completed
3
667
Canada, US, Europe, RoW
TR-701 FA, Tedizolid Phosphate, TR-700 active moiety, Linezolid, Trade name = Zyvox, Generic name = linezolid
Trius Therapeutics LLC
Skin and Subcutaneous Tissue Bacterial Infections
09/11
09/11
NCT01421511 / 2011-002860-26: TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Completed
3
666
US, Europe, RoW
TR-701 FA, Linezolid
Trius Therapeutics LLC
Skin and Subcutaneous Tissue Bacterial Infections
01/13
01/13
NCT02066402: Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Completed
3
598
US, RoW
Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid
Bayer, Merck Sharp & Dohme LLC
Bacterial Infections
03/16
04/16
NCT01967225: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Completed
3
125
Japan
Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
Bayer
Skin Diseases, Infectious
10/16
10/16

Download Options